Insulin Glargine and Fluoxetine Interaction

Understanding the Insulin Glargine and Fluoxetine Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Insulin Glargine belongs to the Long-Acting Insulin class and Fluoxetine belongs to the Selective Serotonin Reuptake Inhibitor (SSRI) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Fluoxetine can increase the effect of insulin, which may cause your blood sugar to drop lower than expected. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Insulin Glargine has 11 total documented interactions on file in this dataset, and Fluoxetine has 68. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Watch for signs of low blood sugar and talk to your doctor about adjusting your medication doses. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Insulin Glargine or Fluoxetine based on a web page, speak with your prescriber or pharmacist before making any change.